Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down before the market opened on Tuesday . The stock had previously closed at $20.89, but opened at $20.07. Nanobiotix shares last traded at $20.1990, with a volume of 25,978 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NBTX. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nanobiotix currently has an average rating of “Hold” and an average target price of $11.00.

Nanobiotix Stock Down 3.2%

The stock has a 50-day simple moving average of $21.25 and a 200 day simple moving average of $14.76.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.